Literature DB >> 17155901

Role of transforming growth factor-beta in cancer progression.

Amy J Galliher1, Jason R Neil, William P Schiemann.   

Abstract

Invasion and metastasis are the most lethal characteristics of cancer and the leading causes of cancer-related death. Transforming growth factor (TGF)-beta is a multifunctional cytokine that normally functions to prevent the uncontrolled proliferation of epithelial, endothelial and hematopoietic cells. Quite dichotomously, however, aberrant genetic or epigenetic events often negate the cytostatic function of TGF-beta in these cells, leading to tumor formation. Once freed from the growth-inhibitory effects of TGF-beta, cancer cells acquire the ability to proliferate, invade and metastasize when stimulated by TGF-beta. A thorough understanding of the molecular mechanisms underlying these paradoxical functions of TGF-beta remains elusive. Here, the authors review the tumor-suppressing and -promoting activities of TGF-beta and discuss the potential use and targeting of the TGF-beta-signaling system to prevent the progression and acquisition of metastatic phenotypes by human malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17155901     DOI: 10.2217/14796694.2.6.743

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  47 in total

1.  Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.

Authors:  Nikolas Balanis; Michael K Wendt; Barbara J Schiemann; Zhenghe Wang; William P Schiemann; Cathleen R Carlin
Journal:  J Biol Chem       Date:  2013-05-07       Impact factor: 5.157

Review 2.  Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?

Authors:  Alex Boye; Yu-Hong Zou; Yan Yang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  TGF-beta induced RBL2 expression in renal cancer cells by down-regulating miR-93.

Authors:  J Shi; Y Zhuang; X K Liu; Y X Zhang; Y Zhang
Journal:  Clin Transl Oncol       Date:  2014-09-03       Impact factor: 3.405

4.  Seeking unique and common biological themes in multiple gene lists or datasets: pathway pattern extraction pipeline for pathway-level comparative analysis.

Authors:  Ming Yi; Uma Mudunuri; Anney Che; Robert M Stephens
Journal:  BMC Bioinformatics       Date:  2009-06-29       Impact factor: 3.169

5.  Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.

Authors:  Teresita Muñoz-Antonia; Mariclara Torrellas-Ruiz; Jonathan Clavell; Linda A Mathews; Carlos A Muro-Cacho; Adriana Báez
Journal:  Int J Otolaryngol       Date:  2009-06-14

6.  Reduced level of the spindle checkpoint protein BUB1B is associated with aneuploidy in colorectal cancers.

Authors:  E Burum-Auensen; P M DeAngelis; A R Schjølberg; J Røislien; O Mjåland; O P F Clausen
Journal:  Cell Prolif       Date:  2008-08       Impact factor: 6.831

7.  Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer.

Authors:  Maozhen Tian; William P Schiemann
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

8.  X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression.

Authors:  Jason R Neil; Maozhen Tian; William P Schiemann
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

9.  Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma.

Authors:  Piotr Daniel; Malgorzata Wagrowska-Danilewicz; Marian Danilewicz; Olga Stasikowska; Ewa Malecka-Panas
Journal:  Int J Colorectal Dis       Date:  2007-03-30       Impact factor: 2.571

10.  S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling.

Authors:  Ran Xie; Matthew P Schlumbrecht; Gregory L Shipley; Susu Xie; Roland L Bassett; Russell R Broaddus
Journal:  Lab Invest       Date:  2009-06-08       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.